ArticleNature cancer2023
Specific regulation of BACH1 by the hotspot mutant p53
Open access · greenAbstract read
In one paragraph
Article in Nature cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
8.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 52 citations in OpenAlex.
- p53-R280S mutation confers lenvatinib resistance in hepatocellular carcinoma via Bcl-2-mediated anti-apoptotic signaling.Molecular and cellular biochemistry · 2026Article
- LFPM inhibition of RING1-mediated p53Cell death and differentiation · 2026Article
- Ferroptosis as an approach to leverage cancer metabolism.Trends in cell biology · 2026Review
- DNA-contact mutant p53 displaces BRCA2 from chromatin and drives R-loop-associated genome instability.Genome biology · 2026Article
- Translating ferroptosis into oncology: challenges, opportunities and future directions.Nature reviews. Clinical oncology · 2026Review
- TAF1 aggravates ferroptosis by promoting the ubiquitin-mediated degradation of nuclear GPX4.Journal of Zhejiang University. Science. B · 2026Article
- A GPX1-OSBPL8 axis mediates noncanonical in vivo ferroptosis and cancer growth suppression.Cell · 2026Article
- Prognostic impact of TP53 mutations in diffuse large B-cell lymphoma.Annals of hematology · 2026Article
- The Multilayered Landscape of Ferroptosis: Plasticity, Propagation, and Evolutionary Perspectives.Antioxidants (Basel, Switzerland) · 2026Review
- Multi-layered integrated shielding: engineering ferroptosis-resistant mesenchymal stem cells for precision therapy of intervertebral disc degeneration.Apoptosis : an international journal on programmed cell death · 2026Review
- The impact of p53 mutation on tumor immune evasion: mechanistic insights and clinical implications.Frontiers in immunology · 2026Review
- Targeting ferroptosis in sepsis-induced cardiomyopathy: mechanisms and therapeutic potential of traditional Chinese Medicine.Frontiers in pharmacology · 2026Review
- Article
- p53-regulated non-apoptotic cell death pathways and their relevance in cancer and other diseases.Nature reviews. Molecular cell biology · 2025Review
- Paeonol regulates glycolytic metabolism by downregulating BACH1 to ameliorate stemness, angiogenesis, and EMT in SiHa cervical cancer cells.Histology and histopathology · 2025Article
- Mutant p53 Gain of Function: Why Many See It, Why Some Do Not.Cancer discovery · 2025Article
- Comprehensive analysis of ferroptosis-related long non-coding RNA and its association with tumor progression and ferroptosis in gastric cancer.BMC gastroenterology · 2025Article
- The Multifaceted Roles of BACH1 in Disease: Implications for Biological Functions and Therapeutic Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Lipogenic enzyme FASN promotes mutant p53 accumulation and gain-of-function through palmitoylation.Nature communications · 2025Article
- Targeting ferroptosis to enhance the efficacy of mesenchymal stem cell-based treatments for intervertebral disc degeneration.International journal of biological sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 1 country.
Zhenyi SuInstitute for Cancer Genetics, and Department of Pathology and Cell Biology, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, USA.
Ning KonInstitute for Cancer Genetics, and Department of Pathology and Cell Biology, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, USA.
Jingjie YiInstitute for Cancer Genetics, and Department of Pathology and Cell Biology, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, USA.
Haiqing ZhaoDepartments of Biochemistry and Molecular Biophysics, Systems Biology, and Medical Sciences in Medicine, Zuckerman Institute Columbia University, New York, NY, USA.ORCID http://orcid.org/0000-0003-1168-5730
Wanwei ZhangDepartment of Microbiology and Immunology, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.ORCID http://orcid.org/0000-0001-9949-1206
Qiaosi TangHerbert Irving Comprehensive Cancer Center, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, USA.
Huan LiInstitute for Cancer Genetics, and Department of Pathology and Cell Biology, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, USA.
Hiroki KobayashiDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Zhiming LiInstitute for Cancer Genetics, and Department of Pathology and Cell Biology, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, USA.ORCID http://orcid.org/0000-0002-5031-8362
Shoufu DuanInstitute for Cancer Genetics, and Department of Pathology and Cell Biology, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, USA.ORCID http://orcid.org/0000-0003-0416-374X
Yanqing LiuInstitute for Cancer Genetics, and Department of Pathology and Cell Biology, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, USA.
Kenneth P OliveHerbert Irving Comprehensive Cancer Center, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, USA.
Zhiguo ZhangInstitute for Cancer Genetics, and Department of Pathology and Cell Biology, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, USA.ORCID http://orcid.org/0000-0002-9451-2685
Barry HonigDepartments of Biochemistry and Molecular Biophysics, Systems Biology, and Medical Sciences in Medicine, Zuckerman Institute Columbia University, New York, NY, USA.
James J ManfrediDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-2234-9097
Anil K RustgiHerbert Irving Comprehensive Cancer Center, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, USA.
Wei GuInstitute for Cancer Genetics, and Department of Pathology and Cell Biology, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, USA. wg8@cumc.columbia.edu.ORCID http://orcid.org/0000-0002-1480-2368
Cancer Genetics (United States) · USColumbia University · USColumbia University Irving Medical Center · USIcahn School of Medicine at Mount Sinai · US
Funding
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3Mp53-mediated metabolic regulation in tumor suppressionR35CA253059 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Wei Gu · 2021 to 2026
$5.3MTargeting cysteine import to induce ferroptotic cell death in pancreatic cancerR01CA215607 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Kenneth P. Olive · 2017 to 2026
$4.0MCell lineage determinants of p53-driven fate outcomes in vivoR01CA257548 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MANFREDI, JAMES J, PRIVES, CAROL · 2021 to 2025
$3.0MGenome-wide structure-based analysis of protein-protein interactions and networksR35GM139585 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BARRY H HONIG · 2021 to 2026
$2.7MCo-regulation of p53 and PD-L1 by the VPRBP-USP2 axis in transcription and ubiquitylationR01CA258390 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Wei Gu · 2022 to 2026
$2.3MNovel small molecule USP7 Inhibitors for p53 activation and cancer therapyR01CA254970 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GU, WEI · 2021 to 2025
$1.8MNCI NIH HHS P30 CA013696NCI NIH HHS R01 CA215607NCI NIH HHS R01 CA254970NCI NIH HHS R01 CA257548NCI NIH HHS R01 CA258390NCI NIH HHS R35 CA253059NIGMS NIH HHS R35 GM139585
Abstract
Although the gain of function (GOF) of p53 mutants is well recognized, it remains unclear whether different p53 mutants share the same cofactors to induce GOFs. In a proteomic screen, we identified BACH1 as a cellular factor that recognizes the p53 DNA-binding domain depending on its mutation status. BACH1 strongly interacts with p53
Indexed as
Gain of Function MutationTumor Suppressor Protein p53Basic-Leucine Zipper Transcription FactorsDown-RegulationMutationProteomicsBasic-Leucine Zipper Transcription FactorsTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.